OrigiMed provides molecular diagnostic information specifically for cancer patients through advanced genomic testing techniques. This enables healthcare providers to make informed treatment decisions based on precise genetic insights, improving patient outcomes and personalized care.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment decisions increasingly rely on understanding the unique genetic characteristics of a patient's tumor. Traditional diagnostic methods may not provide sufficient molecular information to guide personalized treatment strategies, potentially leading to suboptimal outcomes.
Solution
OrigiMed offers advanced molecular diagnostic services for cancer patients, utilizing comprehensive genomic testing to identify specific genetic alterations within tumors. By analyzing DNA and RNA, OrigiMed provides clinicians with detailed insights into the molecular drivers of cancer, informing treatment selection and predicting response to therapy. This precision medicine approach enables healthcare providers to tailor treatment plans to the individual patient, potentially improving efficacy and minimizing adverse effects. OrigiMed's services aim to enhance the accuracy and effectiveness of cancer care through personalized genomic information.
Target Audience
OrigiMed's primary customers are oncologists, pathologists, and other healthcare professionals involved in the diagnosis and treatment of cancer patients.
Features
- Comprehensive genomic profiling of tumor samples using next-generation sequencing (NGS)
- Detection of single nucleotide variants (SNVs), insertions/deletions (indels), copy number alterations (CNAs), and gene fusions
- RNA sequencing for gene expression analysis and detection of transcriptomic alterations
- Liquid biopsy analysis for circulating tumor DNA (ctDNA) to monitor treatment response and detect resistance mechanisms
- Detailed reporting of clinically relevant biomarkers with therapeutic implications
- Integration of genomic data with clinical information for personalized treatment recommendations